155 related articles for article (PubMed ID: 29635632)
41. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine.
Cone EJ; Heit HA; Caplan YH; Gourlay D
J Anal Toxicol; 2006; 30(1):1-5. PubMed ID: 16620524
[TBL] [Abstract][Full Text] [Related]
42. A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain.
Watanabe S; Pereira J; Tarumi Y; Hanson J; Bruera E
J Palliat Med; 2008 May; 11(4):570-4. PubMed ID: 18454609
[TBL] [Abstract][Full Text] [Related]
43. Morphine or hydromorphone: which should be preferred? A systematic review.
Spénard S; Gélinas C; D Trottier E; Tremblay-Racine F; Kleiber N
Arch Dis Child; 2021 Oct; 106(10):1002-1009. PubMed ID: 33461958
[TBL] [Abstract][Full Text] [Related]
44. Effect of preoperative hydromorphone in patients undergoing laparoscopic radical gastrectomy. A double-blind, randomized and controlled trial.
Wang J; Wang N; Zhou H; Wang Y
Saudi Med J; 2018 Oct; 39(10):1023-1027. PubMed ID: 30284586
[TBL] [Abstract][Full Text] [Related]
45. Effects of hydromorphone and morphine intravenous analgesia on plasma motilin and postoperative nausea and vomiting in patients undergoing total hysterectomy.
Liu Y; Yang L; Tao SJ
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5697-5703. PubMed ID: 30229847
[TBL] [Abstract][Full Text] [Related]
46. The role of hydromorphone in cancer pain treatment: a systematic review.
Pigni A; Brunelli C; Caraceni A
Palliat Med; 2011 Jul; 25(5):471-7. PubMed ID: 21708853
[TBL] [Abstract][Full Text] [Related]
47. Clinical effectiveness and safety of OROS® hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients.
Lee KH; Kim MK; Hyun MS; Kim JY; Park KU; Song HS; Lee SA; Lee WS; Bae SH; Ryoo HM; Cho YY
J Opioid Manag; 2012; 8(4):243-52. PubMed ID: 22941852
[TBL] [Abstract][Full Text] [Related]
48. Hydromorphone for acute and chronic pain.
Quigley C
Cochrane Database Syst Rev; 2002; (1):CD003447. PubMed ID: 11869661
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
[TBL] [Abstract][Full Text] [Related]
50. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
[TBL] [Abstract][Full Text] [Related]
52. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial.
Stockler M; Vardy J; Pillai A; Warr D
J Clin Oncol; 2004 Aug; 22(16):3389-94. PubMed ID: 15310785
[TBL] [Abstract][Full Text] [Related]
53. Randomized clinical trial of the 2 mg hydromorphone bolus protocol versus the "1+1" hydromorphone titration protocol in treatment of acute, severe pain in the first hour of emergency department presentation.
Chang AK; Bijur PE; Lupow JB; Gallagher EJ
Ann Emerg Med; 2013 Oct; 62(4):304-10. PubMed ID: 23694801
[TBL] [Abstract][Full Text] [Related]
54. The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients.
Reddy A; Vidal M; Stephen S; Baumgartner K; Dost S; Nguyen A; Heung Y; Kwan S; Wong A; Pangemanan I; Azhar A; Tayjasanant S; Rodriguez E; Waletich J; Lim KH; Wu J; Liu D; Williams J; Yennurajalingam S; Bruera E
J Pain Symptom Manage; 2017 Sep; 54(3):280-288. PubMed ID: 28711751
[TBL] [Abstract][Full Text] [Related]
55. Relative analgesic potencies of morphine and hydromorphone in postoperative pain.
Mahler DL; Forrest WH
Anesthesiology; 1975 May; 42(5):602-7. PubMed ID: 48347
[TBL] [Abstract][Full Text] [Related]
56. Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial.
Miller MG; McCarthy N; O'Boyle CA; Kearney M
J Pain Symptom Manage; 1999 Jul; 18(1):9-16. PubMed ID: 10439568
[TBL] [Abstract][Full Text] [Related]
57. [Postoperative pain therapy with hydromorphone and metamizole. A prospective randomized study in intravenous patient-controlled analgesia (PCA)].
Lehmann KA; Paral F; Sabatowski R
Anaesthesist; 2001 Oct; 50(10):750-6. PubMed ID: 11702324
[TBL] [Abstract][Full Text] [Related]
58. Hydromorphone versus morphine: a historical cohort study to evaluate the quality of postoperative analgesia.
Rodrigues S; Shin D; Conway M; Smulski S; Trenker E; Shanthanna H; Vanniyasingam T; Thabane L; Paul J
Can J Anaesth; 2021 Feb; 68(2):226-234. PubMed ID: 33170454
[TBL] [Abstract][Full Text] [Related]
59. Low-dose ketamine infusion reduces postoperative hydromorphone requirements in opioid-tolerant patients following spinal fusion: A randomised controlled trial.
Boenigk K; Echevarria GC; Nisimov E; von Bergen Granell AE; Cuff GE; Wang J; Atchabahian A
Eur J Anaesthesiol; 2019 Jan; 36(1):8-15. PubMed ID: 30113350
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
